Liminatus Pharma (NASDAQ:LIMN – Get Free Report) posted its earnings results on Friday. The company reported ($0.03) earnings per share for the quarter, FiscalAI reports.
Liminatus Pharma Stock Performance
NASDAQ LIMN traded down $0.01 during trading on Friday, reaching $0.14. The company’s stock had a trading volume of 13,204,123 shares, compared to its average volume of 33,408,202. The business’s fifty day moving average price is $0.12 and its 200-day moving average price is $0.25. Liminatus Pharma has a twelve month low of $0.10 and a twelve month high of $4.33. The firm has a market cap of $7.09 million, a price-to-earnings ratio of -0.32 and a beta of 5.35.
Wall Street Analyst Weigh In
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Liminatus Pharma in a research note on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.
Liminatus Pharma Company Profile
Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.
Featured Stories
- Five stocks we like better than Liminatus Pharma
- Applied Materials Beat Everything but Wall Street’s Expectations for Margins
- Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
- Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing
- AirJoule Technologies: Short Squeeze Setup Amid Rising Risks
Receive News & Ratings for Liminatus Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liminatus Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
